William Blair Issues Pessimistic Estimate for APLT Earnings

Applied Therapeutics, Inc. (NASDAQ:APLT) – William Blair decreased their Q2 2025 earnings per share (EPS) estimates for Applied Therapeutics in a report released on Tuesday, October 22nd. William Blair analyst L. Hanbury-Brown now forecasts that the company will earn ($0.11) per share for the quarter, down from their previous forecast of ($0.10). William Blair currently has a “Strong-Buy” rating on the stock. The consensus estimate for Applied Therapeutics’ current full-year earnings is ($0.48) per share. William Blair also issued estimates for Applied Therapeutics’ Q3 2025 earnings at ($0.08) EPS and FY2025 earnings at ($0.36) EPS.

APLT has been the topic of a number of other research reports. Citigroup increased their price objective on Applied Therapeutics from $8.00 to $11.00 and gave the company a “buy” rating in a research note on Thursday, September 19th. Royal Bank of Canada reiterated an “outperform” rating and set a $12.00 target price on shares of Applied Therapeutics in a research report on Wednesday, July 17th. Finally, Leerink Partners lifted their price target on Applied Therapeutics from $11.00 to $14.00 and gave the company an “outperform” rating in a report on Thursday, September 19th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $12.50.

Applied Therapeutics Stock Up 2.9 %

APLT opened at $8.97 on Thursday. The firm has a market cap of $1.02 billion, a P/E ratio of -4.88 and a beta of 2.04. Applied Therapeutics has a 52 week low of $1.79 and a 52 week high of $9.39. The business’s fifty day simple moving average is $7.08 and its 200 day simple moving average is $5.65.

Applied Therapeutics (NASDAQ:APLT) last posted its earnings results on Wednesday, August 7th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.03). The business had revenue of $0.14 million during the quarter, compared to the consensus estimate of $10.00 million.

Hedge Funds Weigh In On Applied Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Hennion & Walsh Asset Management Inc. lifted its stake in shares of Applied Therapeutics by 34.7% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 265,372 shares of the company’s stock valued at $2,256,000 after purchasing an additional 68,330 shares in the last quarter. Algert Global LLC acquired a new position in Applied Therapeutics during the 2nd quarter worth approximately $110,000. Frazier Life Sciences Management L.P. lifted its position in Applied Therapeutics by 17.1% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 2,286,135 shares of the company’s stock worth $10,676,000 after acquiring an additional 333,278 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in Applied Therapeutics during the 2nd quarter worth approximately $172,000. Finally, Sei Investments Co. acquired a new position in Applied Therapeutics during the 2nd quarter worth approximately $535,000. 98.31% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Applied Therapeutics

In other Applied Therapeutics news, CEO Shoshana Shendelman sold 119,591 shares of Applied Therapeutics stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $5.93, for a total value of $709,174.63. Following the completion of the sale, the chief executive officer now owns 4,690,839 shares in the company, valued at $27,816,675.27. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 8.60% of the stock is owned by company insiders.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.